Advertisement

A prospective study of radical external beam radiotherapy versus external beam radiotherapy combined with intraluminal brachytherapy for primary esophageal cancer

  • Author Footnotes
    1 These authors contributed equally to this work.
    Mingyue Ye
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, China
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
    Dongmei Han
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, China
    Search for articles by this author
  • Zhuang Mao
    Affiliations
    Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, China
    Search for articles by this author
  • Guanghui Cheng
    Correspondence
    Corresponding author. Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, No.126 Xiantai Street, Changchun, China. Tel.: +86-136-1071-2080; fax: +86 431 84995511.
    Affiliations
    Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, China
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.

      Abstract

      PURPOSE

      This study compared the efficacy and side effects of external beam radiotherapy (EBRT) + intraluminal brachytherapy (IBT) with EBRT alone in patients with primary thoracic esophageal cancer.

      MATERIALS AND METHODS

      Between 2013 and 2020, 64 patients with primary thoracic esophageal cancer without surgery received radiotherapy. Thirty-two patients received EBRT + IBT. EBRT dose was 50 Gy, 2 Gy/f, 5 times a week, and IBT dose was 10 Gy, 5 Gy/f, once a week. Thirty-two patients received EBRT alone, and the total dose was 60 Gy. The median followup was 19 months.

      RESULTS

      The local control rates (LCR) of EBRT + IBT and EBRT alone group at 1, 2, and 3 years after treatment were 88% and 72%, 53% and 22%, 25%, and 9%, respectively. The overall survival (OS) of the EBRT + IBT and EBRT alone group at 3 years after treatment were 38% and 9%. The 3-year local recurrence-free survival (LRFS) rates of EBRT + IBT and EBRT alone group were 25% and 9%. Univariate analysis showed that EBRT + IBT could be the prognostic factor improving OS (p = 0.04), and tumor located in the mid-thoracic region exhibited a poorer prognosis on LRFS (p = 0.03). Grade 3 or higher acute side effects included two cases of dysphagia and three cases of bone marrow suppression. Severe late side effects included three cases of fistula, three cases of radiation pneumonia, and five cases of stenosis requiring treatment.

      CONCLUSIONS

      Compared with EBRT alone, EBRT + IBT is an effective treatment modality for T1∼3NanyM0 primary thoracic esophageal cancer with good local control. It can prolong the survival time of patients and has acceptable toxicity.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sung H.
        • Ferlay J.
        • Siegel R.L.
        • et al.
        Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2021; 71: 209-249
        • Shridhar R.
        • Almhanna K.
        • Meredith K.L.
        • et al.
        Radiation therapy and esophageal cancer.
        Cancer Control. 2013; 20: 97-110
        • Nishimura Y.
        • Okuno Y.
        • Ono K.
        • et al.
        External beam radiation therapy with or without high-dose-rate intraluminal brachytherapy for patients with superficial esophageal carcinoma.
        Cancer. 1999; 86: 220-228
        • Ishikawa H.
        • Nonaka T.
        • Sakurai H.
        • et al.
        Usefulness of intraluminal brachytherapy combined with external beam radiation therapy for submucosal esophageal cancer: long-term follow-up results.
        Int J Radiat Oncol Biol Phys. 2010; 76: 452-459
        • Ishikawa H.
        • Sakurai H.
        • Tamaki Y.
        • et al.
        Radiation therapy alone for stage I (UICC T1N0M0) squamous cell carcinoma of the esophagus: indications for surgery or combined chemoradiotherapy.
        J Gastroen Hepatol. 2006; 21: 1290-1296
        • Ishikawa H.
        • Sakurai H.
        • Yamakawa M.
        • et al.
        Clinical outcomes and prognostic factors for patients with early esophageal squamous cell carcinoma treated with definitive radiation therapy alone.
        J Clin Gastroenterol. 2005; 39: 495-500
        • Nemoto K.
        • Yamada S.
        • Hareyama M.
        • Nagakura H.
        • Hirokawa Y.
        Radiation therapy for superficial esophageal cancer: a comparison of radiotherapy methods.
        Int J Radiat Oncol Biol Phys. 2001; 50: 639-644
        • Chauhan A.
        • Kaur P.
        • Annex E.
        Radical external beam radiotherapy with intraluminal high rate dose brachytherapy in patients with carcinoma esophagus.
        Internet J Gastroenterol. 2008; 8
        • Calais G.
        • Dorval E.
        • Louisot P.
        • et al.
        Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for Stages IIB and III esophageal carcinoma: results of a pilot study.
        Int J Radiat Oncol Biol Phys. 1997; 38: 769-775
        • Muijs C.T.
        • Beukema J.C.
        • Mul V.E.
        • et al.
        External beam radiotherapy combined with intraluminal brachytherapy in esophageal carcinoma.
        Radiother Oncol. 2012; 102: 303-308
        • Halder A.
        • Biswas R.
        • Ghosh A.
        • Dastidar A.G.
        Comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: a single institutional study.
        J Contemp Brachytherapy. 2018; 10: 225-231
        • Yorozu A.
        • Dokiya T.
        • Oki Y.
        High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma.
        Int J Radiat Oncol Biol Phys. 1999; 45: 271-275
        • Sharan K.
        • Fernandes D.J.
        • Saxena PU Prakash
        • Banerjee S.
        • Sathian B.
        Treatment outcomes after intraluminal brachytherapy following definitive chemoradiotherapy in patients with esophageal cancer.
        J Cancer Res Ther. 2014; 10: 337-341
        • Khurana R.
        • Dimri K.
        • Lal P.
        • et al.
        Factors influencing the development of ulcers and strictures in carcinoma of the esophagus treated with radiotherapy with or without concurrent chemotherapy.
        J Cancer Res Ther. 2007; 3: 2-7
        • Vuong T.
        • Szego P.
        • David M.
        • et al.
        The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy.
        Int J Radiat Oncol Biol Phys. 2005; 63: 758-764
        • Sharma V.
        • Agarwal J.
        • Dinshaw K.
        • et al.
        Late esophageal toxicity using a combination of external beam radiation, intraluminal brachytherapy and 5-fluorouracil infusion in carcinoma of the esophagus.
        Dis Esophagus. 2000; 13: 219-225
        • Gaspar L.E.
        • Qian C.
        • Kocha W.I.
        • et al.
        A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report.
        Int J Radiat Oncol Biol Phys. 1997; 37: 593-599
        • Welsch J.
        • Kup P.G.
        • Nieder C.
        • et al.
        Survival and symptom relief after palliative radiotherapy for esophageal cancer.
        J Cancer. 2016; 7: 125-130
        • Caspers R.J.
        • Zwinderman A.H.
        • Griffioen G.
        • et al.
        Combined external beam and low dose rate intraluminal radiotherapy in oesophageal cancer.
        Radiother Oncol. 1993; 27: 7-12
        • Nag P.
        • Gurjar O.P.
        • Bhandari V.
        • et al.
        Intraluminal brachytherapy boost following external beam radiotherapy with concurrent chemotherapy of oesophagus carcinoma: results of a prospective observational study.
        Cancer Radiother. 2018; 22: 163-166
        • Versteijne E.
        • van Laarhoven H.W.M.
        • van Hooft J.E.
        • et al.
        Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern.
        Dis Esophagus. 2015; 28: 453-459
        • Chao Y.K.
        • Chan S.C.
        • Liu Y.H.
        • et al.
        Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
        Anna Surg. 2009; 249: 392-396
        • Wang B.Y.
        • Goan Y.G.
        • Hsu P.K.
        • et al.
        Tumor length as a prognostic factor in esophageal squamous cell carcinoma.
        Ann Thorac Surg. 2011; 91: 887-893